Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol 2004; 251: 3 A/11.Goodin DS (2004) Disease-modifying therapy in MS: a critical review of the literature. Part I. Analysis of clinical trial errors. J...
Continuous assessment of infectious risks before, during and after disease-modifying therapy for MS, especially when using intravenous drugs, has increasing clinical relevance Experience with the recently approved oral MS disease-modifying therapies illustrates that even after approval, new treatment-associate...
Continuous assessment of infectious risks before, during and after disease-modifying therapy for MS, especially when using intravenous drugs, has increasing clinical relevance Experience with the recently approved oral MS disease-modifying therapies illustrates that even after approval, new treatment-associate...
此外,在风湿病领域的文献中,我们看到这样的英文和译文:Therefore,substantial revenue opportunity for conventional disease-modifying antirheumatic drugs(DMARDs)remains in early lines of therapy[译文:因此,传统的改善疾病的抗风湿药物(DMARDs)的大...
Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study Disease-modifying therapy (DMT) use in multiple sclerosis (MS) has increased significantly. However, the impact of DMTs on healthcare use is limited and...
Systemic sclerosis (SSc) has the highest cause-specific mortality of all the connective tissue diseases, and the aetiology of this complex and heterogeneous condition remains an enigma. Current disease-modifying therapies for SSc predominantly target inf
disease-modifying therapy 疾病修饰疗法 双语对照 词典结果：disease-modifying therapy [医]病性改善疗法，病情调养法;
There are multiple disease-modifying therapy options inMS. • For a variety of reasons, guidelines and treatment access vary across Europe. • Current practice at initiation, switch and escalation in relapsing MS is reviewed. • The case is made for a European treatment guideline that informs...
Only two types of drugs are currently approved for the treatment of AD: inhibitors of acetyl cholinesterase, which symptomatically enhance cognitive state to some degree but are not disease modifying; and the adamantane derivative, memantine. Memantine preferentially blocks excessive NMDA receptor ...
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzhe... advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment...